IR@PKUHSC  > 北京大学第二临床医学院  > 血液科
学科主题临床医学
Current status and development of hematopoietic stem cell transplantation in China: a report from Chinese Hematopoietic Stem Cell Transplantation Register Group
Xu Lan-ping; Huang Xiao-jun
关键词Hematopoietic Stem Cell Transplantation Registration Unrelated Haploidentical
刊名CHINESE MEDICAL JOURNAL
2011-08-20
DOI10.3760/cma.j.issn.0366-6999.2011.16.027
124期:16页:2548-2555
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Medicine, General & Internal
资助者Program for Innovative Research Team in University ; Ministry of Health of China ; Program for Innovative Research Team in University ; Ministry of Health of China
研究领域[WOS]General & Internal Medicine
关键词[WOS]HLA-MISMATCHED/HAPLOIDENTICAL BLOOD ; BONE-MARROW-TRANSPLANTATION ; DONOR LYMPHOCYTE INFUSION ; RISK ACUTE-LEUKEMIA ; HEMATOLOGICAL MALIGNANCIES ; DEPLETION ; PROPHYLAXIS ; OUTCOMES ; RELAPSE ; GVHD
英文摘要

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has three decades history in China. During these periods, the number of HSCT has been increasing, donor and stem cell sources were expanded, indication of diseases and patients for HSCT extended. Forty-two HSCT units offered their data 1-6 times from July 2007 to June 2010. The annual increase rates were 8.8% to 10.8%. Matched sibling donor is 41%, mismatched related/haploidentical donor is 24%, unrelated volunteer donor is 16%, and umbilical cord blood is 2%. The indications of major disease entities are acute myeloid leukemia (AML, 35%), acute lymphobastic leukemia (ALL, 25%), chronic myeloid leukemia (CML, 21%), and myelodysplastic syndrome (MDS, 8%). The different opinions on the indication of HSCT were supported by some trials, matched/haploidentical HSCT fit for middle or high risk ALL and AML in first complete remission (CR1), the international prognosis score system (IPSS) - middle-II/high risk MDS, CML in advanced stage and so on, when patients have no matched sibling donor. In the Peking University Institute of Hematology, Peking University People′s Hospital, haploidentical HSCT has received a comparable result to matched simbling donor HSCT and unrelated matched donor HSCT; we suggest haploidentical donor might be a routine alternative donor for high-risk patents who need an urgent HSCT without matched related donor in special center. Chin Med J 2011;124(16):2548-2555

语种英语
所属项目编号IRT0702 ; 200802027
资助者Program for Innovative Research Team in University ; Ministry of Health of China ; Program for Innovative Research Team in University ; Ministry of Health of China
WOS记录号WOS:000294584200027
Citation statistics
Cited Times:5[WOS]   [WOS Record]     [Related Records in WOS]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/52658
Collection北京大学第二临床医学院_血液科
作者单位Peking Univ, Peoples Hosp, Inst Hematol, Beijing 100044, Peoples R China
Recommended Citation
GB/T 7714
Xu Lan-ping,Huang Xiao-jun. Current status and development of hematopoietic stem cell transplantation in China: a report from Chinese Hematopoietic Stem Cell Transplantation Register Group[J]. CHINESE MEDICAL JOURNAL,2011,124(16):2548-2555.
APA Xu Lan-ping,&Huang Xiao-jun.(2011).Current status and development of hematopoietic stem cell transplantation in China: a report from Chinese Hematopoietic Stem Cell Transplantation Register Group.CHINESE MEDICAL JOURNAL,124(16),2548-2555.
MLA Xu Lan-ping,et al."Current status and development of hematopoietic stem cell transplantation in China: a report from Chinese Hematopoietic Stem Cell Transplantation Register Group".CHINESE MEDICAL JOURNAL 124.16(2011):2548-2555.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
谷歌学术
谷歌学术Similar articles in
[Xu Lan-ping]'s Articles
[Huang Xiao-jun]'s Articles
百度学术
百度学术Similar articles in
[Xu Lan-ping]'s Articles
[Huang Xiao-jun]'s Articles
必应学术
必应学术Similar articles in
[Xu Lan-ping]'s Articles
[Huang Xiao-jun]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.